About this episode
In this episode, Tamara and Scott delve into the dynamic realm of pharmacogenomics within the long-term care. Covering its advantageous impacts and supported by research demonstrating its value, we offer an insightful overview of the presence and significance of pharmacogenomics in long-term care. Dr. Scott Stewart: linkedin.com/in/scott-stewart-34973870 Dr. Tamara Ruggles: linkedin.com/in/tamara-ruggles-491882251 References: - Jokanovic N, Jamsen KM, Tan ECK, Dooley MJ, Kirkpatrick CM, Bell JS. Prevalence and Variability in Medications Contributing to Polypharmacy in Long-Term Care Facilities. Drugs Real World Outcomes. 2017;4(4):235-245. doi:10.1007/s40801-017-0121-x - Saldivar JS, Taylor D, Sugarman EA, et al. Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility. Pharmgenomics Pers Med. 2016;9:1-6. Published 2016 Jan 19. doi:10.2147/PGPM.S93480 - Kistler CE, Austin CA, Liu JJ, et al. The feasibility and potential of pharmacogenetics to reduce adverse drug events in nursing home residents. J Am Geriatr Soc. 2022;70(5):1573-1578. doi:10.1111/jgs.17679 - Hayashi M, Hamdy DA, Mahmoud SH. Applications for Pharmacogenomics in Pharmacy Practice: A Scoping Review. Res Social Adm Pharm. 2021. Epublication ahead of print. - Rodriguez-Escudero I, Cedeno JA, Rodriguez-Nazario I, et al. Assessment of the Clinical Utility of Pharmacogenetic Guidance in a Comprehensive Medication Management Service. J Am Coll Clin Pharm. 2020;3(6):1028–1037. - PGx in the Long-Term Care Environment. RxGenomix. Accessed January 30, 2024. https://rxgenomix.com/insight/pgx-in-the-long-term-care-environment/ Scott Stewart PharmD Tamara Ruggles PharmD BCGP